VYNE Therapeutics Inc.
VYNE
$1.43
-$0.45-23.94%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -30.58% | -38.89% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -30.58% | -38.89% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -30.58% | -38.89% | |||
| SG&A Expenses | 6.95% | -9.85% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -2.71% | 24.71% | |||
| Operating Income | 2.45% | -25.92% | |||
| Income Before Tax | 1.21% | -29.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1.18% | -29.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1.11% | -29.25% | |||
| EBIT | 2.45% | -25.92% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 1.16% | -29.24% | |||
| Normalized Basic EPS | 1.23% | -29.37% | |||
| EPS Diluted | 1.16% | -29.24% | |||
| Normalized Diluted EPS | 1.23% | -29.37% | |||
| Average Basic Shares Outstanding | 0.02% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.02% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||